Yazen generated approximately $17.3 million in revenue in 2024, up from $218 K in 2022, when it pivoted to focus on weight-loss services. The company now serves around 42K active patients, up from 20K in late 2024.

Yazen operates in seven European markets—Sweden, the Netherlands, Spain, Germany, Norway, the UK, and Denmark—with the Netherlands emerging as its fastest-growing region.

Yazen closed a $21.3 million (€19.5 million) Series A in November 2024, led by Evli Growth Partners and Helsana HealthInvest, with participation from existing investors Almaz Capital and Yabeo and new investors Luminar Ventures and Aggregate Media.

The company previously raised $3.4 million (€3.1 million) in 2023, following its initial seed funding after pivoting from testosterone therapy to weight loss services in 2022.

In total, Yazen has raised approximately $24.6 million (€22.6 million) across all funding rounds.

Yazen is a digital obesity treatment platform that combines GLP-1 medications like Wegovy and Mounjaro with structured lifestyle coaching delivered via a mobile app. The service targets adults with a BMI of 27 or higher seeking medical rather than surgical weight loss.

The user journey starts with a free digital health screening in the app, then a consultation with a nurse. Eligible patients receive a lab kit for blood work, with the standard panel provided at no cost. A licensed obesity physician reviews the lab results and prescribes an appropriate GLP-1 medication dose along with a personalized treatment plan.

Electronic prescriptions route to partner pharmacies for home delivery or pickup, and patients access their care team through the app. The care team includes a primary YazenCoach with 24-hour response commitments, plus dietitians, psychologists, physiotherapists, and doctors available for video calls and messaging.

The app delivers daily micro-learning content through the Yazen Commit program on topics such as protein intake and craving management. Patients can log weight, meals, and steps, and connect smart devices like scales and fitness trackers for automated data collection.

The program runs in two phases: an intensive Change phase lasting 12-24 months focused on weight loss, followed by a lower-cost Clarity maintenance phase launching in 2025. Yazen reports real-world data of 16-20% weight loss at 12-18 months with 70% retention.

Yazen operates a B2C subscription model priced at approximately €90 per month for its comprehensive obesity treatment service. The company provides integrated care rather than acting solely as a medication access point, with weight management delivered through coordinated clinical and behavioral support.

The business model separates the service fee from medication costs. Patients pay Yazen's monthly subscription for access to medical consultations, lifestyle coaching, and the digital platform, while purchasing prescribed medications directly from partner pharmacies at standard retail prices.

This structure allows Yazen to avoid being classified as a pill mill while maintaining predictable recurring revenue. The company's cost structure includes licensed medical professionals, technology platform maintenance, and partnerships with pharmacies and data providers for lab work and device integrations.

Yazen's approach to medication dosing focuses on optimization rather than maximization, often prescribing lower doses than standard protocols to reduce side effects and drug costs for patients. This clinical differentiation aims to improve patient retention and outcomes while potentially reducing the total cost of treatment.

The company is developing a B2B offering called Yazen for Business, targeting employers who want to provide obesity treatment as an employee benefit. This enterprise channel could expand the addressable market beyond individual consumers paying out-of-pocket.

Revenue expansion occurs primarily through geographic growth and customer base expansion rather than price increases, as the company maintains consistent pricing across markets while scaling its care delivery infrastructure.

Novo Nordisk and Eli Lilly have launched direct-to-consumer programs that bypass traditional telehealth intermediaries. NovoCare offers Wegovy at $499 monthly with home delivery, while LillyDirect provides similar pricing for Zepbound vials.

These pharmaceutical companies are integrating with existing telehealth platforms like Hims, Ro, and LifeMD to maintain brand visibility while capturing margins previously held by digital health companies. This vertical integration pressures Yazen's medication fulfillment model and pricing power.

The pharmaceutical companies' direct channels reduce differentiation opportunities for platforms like Yazen, as patients can access the same medications at standardized prices without additional service layers.

Ro's Body membership serves over 160,000 patients with 15.8% mean weight loss at 12 months, indicating the scale advantages of established telehealth operators. Hims & Hers has built real-world evidence databases and uses aggressive paid marketing strategies.

These platforms benefit from vertical integration, including in-house pharmacies, laboratory services, and coaching programs. Their established infrastructure and customer acquisition capabilities create competitive pressure on European-focused players like Yazen.

Noom represents another category of competitor, combining digital health tools with behavioral change programs. The company competes with both traditional weight management services like WeightWatchers and digital platforms, creating a hybrid model that addresses the psychological aspects of weight loss.

Manual and Numan both started in sexual health before expanding into weight loss treatments in 2023. Manual raised £29.2 million and operates in Brazil and the UK, while Numan expects close to $200 million in revenue for 2025 with weight loss representing the majority of its business.

These companies benefit from existing customer relationships and established telehealth operations, allowing them to cross-sell weight loss services to established user bases. Their geographic focus and regulatory experience in European markets create direct competition for Yazen's expansion plans.

Local competitors in individual European markets pose additional challenges, particularly in countries with established healthcare technology ecosystems and specific regulatory requirements for medical services.

Yazen is developing a Clarity maintenance phase launching in 2025 that will provide lower-cost, ongoing support for patients who have completed initial weight loss treatment. This maintenance tier could retain customers for years beyond the initial treatment period, expanding lifetime value.

The company's partnership with Withings provides access to detailed body composition data including fat percentage, visceral fat, and muscle mass. This data allows expansion into metabolic health programs addressing type 2 diabetes remission, fatty liver disease, and cardiovascular risk reduction using the same coaching infrastructure.

Connected health devices allow reimbursable remote patient monitoring in markets like Germany and the UK, where digital therapeutics can qualify for public healthcare coverage. This hardware-enabled monitoring could expand the addressable market beyond cash-pay customers.

The involvement of Helsana HealthInvest in Yazen's Series A indicates demand from insurance companies seeking to reduce obesity-related claims through preventive digital interventions. Offering Yazen as a covered benefit could expand the addressable population by 10-20x compared to the current cash-pay model.

Yazen's compliance with GDPR and Swedish healthcare regulations permits direct contracting with European health systems. Public sector contracts could provide large-scale patient access while diversifying revenue beyond individual subscriptions.

The company is developing Yazen for Business to target employers seeking comprehensive weight management benefits for their workforce. This B2B channel uses the same clinical infrastructure while accessing corporate healthcare budgets rather than individual consumer spending.

With Series A funding, Yazen expanded from three core countries in 2023 to seven markets in 2025, with plans for further European expansion. Large markets like France, Italy, and Central/Eastern Europe remain unaddressed, leaving white space for geographic growth.

The company's acquisition of Danish telehealth provider Medstart is part of a strategy to use M&A to accelerate regulatory approval and market entry. Similar acquisitions could accelerate expansion into additional European markets with established local operations.

Yazen's regulatory infrastructure and clinical protocols are built for pan-European use to reduce the complexity of entering new markets compared to building country-specific solutions from scratch.

Pharmaceutical disintermediation: Novo Nordisk and Eli Lilly's direct-to-consumer programs at $499 monthly pricing could commoditize medication access and reduce the value proposition of integrated platforms like Yazen. As pharmaceutical companies capture more of the value chain, digital health intermediaries face margin compression and reduced differentiation opportunities.

Regulatory scrutiny: European regulators are increasing oversight of telehealth marketing practices, particularly around influencer partnerships and direct-to-consumer medical advertising. Yazen's previous regulatory issues with promotional content in the UK indicate the compliance risks that could limit marketing effectiveness and geographic expansion plans.

Market saturation: The weight loss telehealth space is becoming increasingly crowded with well-funded competitors like Manual, Numan, and expanding U.S. platforms. As GLP-1 drug shortages resolve and supply normalizes, competition will likely shift toward price-based differentiation, potentially eroding Yazen's premium positioning and subscription pricing power.